JP4486494B2 - 生物学的製剤 - Google Patents

生物学的製剤 Download PDF

Info

Publication number
JP4486494B2
JP4486494B2 JP2004501459A JP2004501459A JP4486494B2 JP 4486494 B2 JP4486494 B2 JP 4486494B2 JP 2004501459 A JP2004501459 A JP 2004501459A JP 2004501459 A JP2004501459 A JP 2004501459A JP 4486494 B2 JP4486494 B2 JP 4486494B2
Authority
JP
Japan
Prior art keywords
seq
antibody molecule
antibody
cdr
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004501459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506955A (ja
JP2006506955A5 (enExample
Inventor
ポッペルウェル、アンドリュー、ジョージ
ティクル、サイモン、ピーター
レディマン、ヘザー、マーガレット
Original Assignee
ユセベ ファルマ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4486494(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユセベ ファルマ ソシエテ アノニム filed Critical ユセベ ファルマ ソシエテ アノニム
Publication of JP2006506955A publication Critical patent/JP2006506955A/ja
Publication of JP2006506955A5 publication Critical patent/JP2006506955A5/ja
Application granted granted Critical
Publication of JP4486494B2 publication Critical patent/JP4486494B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004501459A 2002-05-02 2003-05-02 生物学的製剤 Expired - Lifetime JP4486494B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009205660A Division JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤

Publications (3)

Publication Number Publication Date
JP2006506955A JP2006506955A (ja) 2006-03-02
JP2006506955A5 JP2006506955A5 (enExample) 2008-10-23
JP4486494B2 true JP4486494B2 (ja) 2010-06-23

Family

ID=9935990

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004501459A Expired - Lifetime JP4486494B2 (ja) 2002-05-02 2003-05-02 生物学的製剤
JP2009205660A Expired - Lifetime JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤
JP2013140245A Expired - Lifetime JP5920934B2 (ja) 2002-05-02 2013-07-04 生物学的製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009205660A Expired - Lifetime JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤
JP2013140245A Expired - Lifetime JP5920934B2 (ja) 2002-05-02 2013-07-04 生物学的製剤

Country Status (34)

Country Link
US (8) US7355011B2 (enExample)
EP (1) EP1504035B9 (enExample)
JP (3) JP4486494B2 (enExample)
KR (3) KR101386376B1 (enExample)
CN (3) CN103172742B (enExample)
AT (1) ATE462729T3 (enExample)
AU (1) AU2003223007C1 (enExample)
BE (1) BE2017C068I2 (enExample)
CA (1) CA2484420C (enExample)
CO (1) CO5631451A2 (enExample)
CY (3) CY1110134T1 (enExample)
DE (1) DE60331910D1 (enExample)
DK (1) DK1504035T6 (enExample)
EC (1) ECSP045470A (enExample)
ES (1) ES2341708T7 (enExample)
FR (1) FR17C1062I2 (enExample)
GB (1) GB0210121D0 (enExample)
HU (2) HUS1700056I1 (enExample)
IL (1) IL164923A (enExample)
LT (2) LTC1504035I2 (enExample)
LU (2) LUC00058I2 (enExample)
MX (1) MXPA04010787A (enExample)
NL (1) NL300920I2 (enExample)
NO (3) NO336201B3 (enExample)
NZ (1) NZ536757A (enExample)
PL (1) PL218433B1 (enExample)
PT (1) PT1504035E (enExample)
RU (1) RU2342401C2 (enExample)
SG (1) SG161744A1 (enExample)
SI (1) SI1504035T1 (enExample)
TW (1) TWI324161B (enExample)
UA (1) UA92580C2 (enExample)
WO (1) WO2003093320A2 (enExample)
ZA (1) ZA200408851B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010022372A (ja) * 2002-05-02 2010-02-04 Ucb Pharma Sa 生物学的製剤

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
BR122019027966B8 (pt) * 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
TW200630106A (en) * 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PT2032606E (pt) * 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
WO2009124109A1 (en) * 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
JP2015516984A (ja) * 2012-04-26 2015-06-18 バイオアトラ、エルエルシー 抗ｃｄ２２抗体
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
CN104582717B (zh) 2012-07-19 2018-03-13 雷德伍德生物科技股份有限公司 对cd22有特异性的抗体及其使用方法
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
WO2017083306A1 (en) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN112888709B (zh) 2018-03-30 2024-10-29 优瑞科生物技术公司 标靶cd22的构建体和其用途
EP4130040A4 (en) * 2020-04-02 2024-05-01 Nanjing Iaso Biotechnology Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
WO2022042494A1 (zh) * 2020-08-27 2022-03-03 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
US20250129180A1 (en) * 2021-08-27 2025-04-24 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133528T2 (de) * 1990-06-27 2006-09-07 Princeton University Proteinkomplex p53/p90
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
JP2001510329A (ja) * 1996-11-01 2001-07-31 スミスクライン・ビーチャム・コーポレイション ヒトモノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
EP1232392B2 (de) * 1999-10-12 2014-04-02 Oxoid (Ely) Limited Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP2004502742A (ja) * 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR122019027966B8 (pt) * 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010022372A (ja) * 2002-05-02 2010-02-04 Ucb Pharma Sa 生物学的製剤

Also Published As

Publication number Publication date
WO2003093320A2 (en) 2003-11-13
CY2017046I2 (el) 2018-12-12
US20160326247A1 (en) 2016-11-10
CA2484420C (en) 2014-09-16
CN1662558A (zh) 2005-08-31
US20120302739A1 (en) 2012-11-29
CO5631451A2 (es) 2006-04-28
MXPA04010787A (es) 2005-03-07
FR17C1062I2 (fr) 2020-05-29
ES2341708T3 (es) 2010-06-25
KR101238970B1 (ko) 2013-03-04
NO20044742L (no) 2004-12-22
ATE462729T3 (de) 2010-04-15
CY2017045I1 (el) 2019-11-27
JP2006506955A (ja) 2006-03-02
JP5377173B2 (ja) 2013-12-25
GB0210121D0 (en) 2002-06-12
CA2484420A1 (en) 2003-11-13
FR17C1062I1 (enExample) 2018-02-16
EP1504035B8 (en) 2018-02-28
US7355011B2 (en) 2008-04-08
CY2017046I1 (el) 2018-12-12
IL164923A0 (en) 2005-12-18
CN103172742A (zh) 2013-06-26
NO2017069I1 (no) 2017-12-21
US20170145114A1 (en) 2017-05-25
EP1504035B1 (en) 2010-03-31
LTPA2017044I1 (lt) 2018-01-10
ES2341708T7 (es) 2018-04-11
DK1504035T3 (da) 2010-06-07
NO2017068I1 (no) 2017-12-21
AU2003223007C1 (en) 2019-08-08
NO336201B1 (no) 2015-06-15
US20100021995A1 (en) 2010-01-28
HK1071762A1 (en) 2005-07-29
EP1504035B9 (en) 2018-10-17
CN101134779B (zh) 2013-03-13
EP1504035A2 (en) 2005-02-09
NZ536757A (en) 2006-06-30
PT1504035E (pt) 2010-06-07
ECSP045470A (es) 2005-01-28
RU2342401C2 (ru) 2008-12-27
DK1504035T6 (en) 2018-03-12
SI1504035T1 (sl) 2010-07-30
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
WO2003093320A3 (en) 2004-02-05
HUS1700055I1 (hu) 2018-07-30
CN100384878C (zh) 2008-04-30
CN103172742B (zh) 2016-05-11
KR20110004463A (ko) 2011-01-13
US7919606B2 (en) 2011-04-05
AU2003223007B2 (en) 2009-07-16
BE2017C068I2 (enExample) 2022-08-09
DE60331910D1 (de) 2010-05-12
HUS1700056I1 (hu) 2018-07-30
IL164923A (en) 2012-03-29
CY1110134T1 (el) 2015-01-14
KR101386376B1 (ko) 2014-04-16
US20030235869A1 (en) 2003-12-25
AU2003223007A1 (en) 2003-11-17
US20210371547A1 (en) 2021-12-02
PL218433B1 (pl) 2014-12-31
LUC00058I1 (enExample) 2017-12-27
NL300920I1 (enExample) 2018-01-03
HK1186479A1 (zh) 2014-03-14
LTC1504035I2 (lt) 2022-04-11
JP2010022372A (ja) 2010-02-04
LUC00058I2 (enExample) 2018-02-26
LTPA2017043I1 (lt) 2018-01-10
US20070059307A1 (en) 2007-03-15
US20110165659A1 (en) 2011-07-07
RU2004135103A (ru) 2005-10-27
LUC00057I1 (enExample) 2017-12-27
PL373277A1 (en) 2005-08-22
UA92580C2 (ru) 2010-11-25
NL300920I2 (nl) 2021-04-15
JP5920934B2 (ja) 2016-05-18
SG161744A1 (en) 2010-06-29
EP1504035B3 (en) 2017-12-20
ZA200408851B (en) 2006-01-25
US8895714B2 (en) 2014-11-25
TW200307690A (en) 2003-12-16
JP2013230158A (ja) 2013-11-14
TWI324161B (en) 2010-05-01
CY2017045I2 (el) 2019-11-27
CN101134779A (zh) 2008-03-05
KR20050025167A (ko) 2005-03-11
LUC00057I2 (enExample) 2018-02-26
KR101156796B1 (ko) 2012-06-21

Similar Documents

Publication Publication Date Title
JP5920934B2 (ja) 生物学的製剤
HK1071762B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
HK1186479B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
BRPI0309730B1 (pt) Molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080904

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100305

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100326

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4486494

Country of ref document: JP

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130402

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130402

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140402

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250